Covid-19 Vaccine
-
Covaxin has ‘excellent track record’, says Bharat Biotech after study details side effects
Scroll Staff
-
AstraZeneca vaccine was key part of global Covid-19 response but plagued by misinformation
Michael Head, The Conversation
-
Absolute vs relative risk: AstraZeneca faces case in the UK for ‘inflating’ vaccine efficacy
Christian Yates, The Conversation
-
Nobel Prize in Medicine awarded to scientists whose work enabled mRNA Covid vaccines
Scroll Staff
-
Google ads paying for porn, propaganda, piracy and more
Craig Silverman, ProPublica Ruth Talbot, ProPublica
-
Covid vaccine: Moderna sues Pfizer, BioNTech for patent infringement
Scroll Staff
-
Wimbledon 2022: Novak Djokovic stands by no vaccination stance, likely to miss US Open
AFP
-
Coronavirus: India registers 17,336 new cases – highest daily count in four months
Scroll Staff
-
Covid-19: A combination of vaccination and prior infection offers more immunity than either alone
Grace C Roberts, The Conversation Lena Glaser, The Conversation
-
Herd immunity was once considered our best bet against Covid-19. Here’s why it has become irrelevant
Hassan Vally, The Conversation
-
As new coronavirus variants of concern emerge in the future, booster shots may need updates
David R Martinez, The Conversation
-
Covid-19: India approves Biological E’s Corbevax as first mix-and-match booster vaccine
Scroll Staff
-
A second booster? It’s time scientists shift focus to vaccines with long-lived antibody response
Prakash Nagarkatti, The Conversation Mitzi Nagarkatti, The Conversation
-
Why few Indians are lining up for Covid-19 booster doses
Tabassum Barnagarwala
-
Covid-19 vaccines are not mandatory, Centre tells Supreme Court
Scroll Staff
-
‘I was worried sick I was going to fall short:’ Adar Poonawalla on manufacturing a Covid-19 vaccine
Barkha Dutt
-
A new TB vaccine could be a game changer for India and South Africa
Matthew Quaife, The Conversation Finn McQuaid, The Conversation
-
Is Omicron nature’s way of curbing the pandemic?
Prakash Nagarkatti, The Conversation Mitzi Nagarkatti, The Conversation
-
Already approved in India, a new patent-free Covid-19 vaccine could be a game changer globally
Maureen Ferran, The Conversation
-
Vaccines for children in 12-14 age group likely from March, says Covid-19 task force chief
Scroll Staff